Preliminary readout from November 2017 showed 5.1% diagnosis when using Zio Patch versus 0.6% when patients relied solely on routine clinical diagnosis.
Zio heart monitor results trial#
This clinical trial is to determine if the Zio Patch is able to more efficiently detect AF versus routine care alone. These results were presented at the 3 rd European Stroke Organization Conference in May of 2017 where it was recognized that the convenience of a patch-based monitor with 14-day continuous monitoring was more optimal than other methods in detecting AF. The random testing of 116 subjects showed Zio Patch enabling detection of 16.1% AF instances versus 2.1% in patients with Holter monitor.
Maximum sales potential should be around $2M per representative, reached once in their 3 rd year in service or slightly longer.Ī study and clinical trial labeled Early Prolonged Ambulatory Cardiac Monitoring after Stroke (EPACS) assessed that Zio Patch was able to detect atrial fibrillation (AF), in transient ischemic attacks (sometimes called mini-strokes) at a higher rate when compared to the industry standard usage of a Holter monitor. RBC Capital estimates 126 representatives and 27 sales managers by the end of 2018, and up to 150 over time. In ‘Phase 2’ of it strategy, management has plans to continue increasing its team and add territory managers as well. There is also an online platform (app and PC) where patients are encouraged to keep a log of any occurrences.įrom a team of 60 quota-carrying sales representatives in 1Q2016, iRhythm had expanded to 76 reps and 23 sales managers by 3Q2017, most likely closing out 2017 with 86. Once the 14 day period is finished, the patient sends his sensor back to iRyhtm where the information is uploaded to their cloud-based data bank, analyzed, compiled and sent to their physician for diagnosis. A trigger button on the sensor can be pressed to mark occasions when experiencing symptoms or events such as shortness of breath, dizziness, irregular heartbeat or any other issues. For 14 days, the device will continuously monitor cardiac activity. More commonly referred to as the Zio Patch, is a discreet sensor that a patient attaches to their chest – it has its own proprietary adhesive backing. Their single product Zio XT is complimented by Zio Service, which compiles the massive amounts of data collected by the monitor and, though proprietary algorithms, condenses the equivalent of 10,000 pages of information to around 15 pages of usable output which is then forwarded to the patient’s physician. IRhythm Technologies (IRTC) is a medical device company that manufactures heart monitoring devices for the detection of cardiac arrhythmia and related conditions. IRhythm Technologies (IRTC) – Listening To Your Heart
0 kommentar(er)
